Vivani Medical Cleared to Start Phase 1 Trial for Semaglutide Implant in Obesity
VANI sits 34% above its 52-week low of $0.923.
Summary
Vivani Medical has received regulatory approval to initiate SLIM-1, a Phase 1 clinical trial for its NPM-139 semaglutide implant in obesity. This is a significant step for the clinical-stage biotech, moving its lead GLP-1 candidate into human trials for a major indication. The news builds on the successful first-in-human trial results for NPM-139 reported on June 4th and follows substantial insider stock purchases by a director in recent months, indicating strong confidence. The SLIM-1 trial will primarily assess safety, tolerability, and pharmacokinetics, with weight loss as a secondary endpoint. Successful results could pave the way for a dose-ranging efficacy trial (SLIM-2).
At the time of this announcement, VANI was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $105.2M. The 52-week trading range was $0.92 to $1.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.